PALISADE BIO, INC. Adjustments to Additional Paid in Capital, Warrant Issued
PALISADE BIO, INC. (PALI) reported Adjustments to Additional Paid in Capital, Warrant Issued of $2.17 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2024-03-26
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2023-03-31 was $2.17M.
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-06-30 was $16.00K.
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for fiscal 2022 was $1.43M, a 8818.75% increase from fiscal 2021.
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for fiscal 2021 was $16.00K, a 44.83% decline from fiscal 2020.
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for fiscal 2020 was $29.00K.
- PALISADE BIO, INC. adjustments to additional paid in capital, warrant issued for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2023-03-31 | $2.17M 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $1.43M 10-K · filed 2024-03-26 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $16.00K derived: sum of 3 quarters · filed 2023-03-22 | $16.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $16.00K derived: sum of 2 quarters · filed 2022-11-14 | $16.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $16.00K 10-Q · filed 2022-08-15 | $16.00K 10-Q · filed 2022-08-15 | ||
| 2020-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $29.00K derived: sum of 2 quarters · filed 2022-03-17 | $29.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $10.00K 10-Q · filed 2021-11-12 | $10.00K 10-Q · filed 2021-11-12 | ||
| 2015-12-31 | $0.00 10-K · filed 2016-03-14 | |||
| 2014-12-31 | $3.11M 10-K · filed 2016-03-14 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $0.00 derived: sum of 2 quarters · filed 2014-03-10 | $1.09M 10-K · filed 2014-03-10 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-09 | $1.09M 10-Q · filed 2011-11-09 | ||
| 2011-06-30 | $1.09M 10-Q/A · filed 2011-09-23 | |||
| 2010-12-31 | $8.45M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |